Long-term data from PARTNER 3 continue to mature. The 7-year outcomes of the low-risk randomised trial have now been reported (NEJM, 2026), extending follow-up of about 1,000 low-surgical-risk patients with severe aortic stenosis randomised to transcatheter (TAVR, Sapien 3) versus surgical (SAVR) valve replacement.
Established 5-year context. The primary composite of death, stroke or rehospitalisation was similar between arms at 5 years (TAVR 22.8% vs SAVR 27.2%), reflecting an early TAVR advantage at 1 year (8.5% vs 15.6%) that flattened between years 1 and 5. Quality of life converged (KCCQ-OS 86.2 vs 85.9), mean gradients were comparable (about 12.7 vs 11.7 mmHg), and bioprosthetic valve failure was low and similar (3.3% vs 3.8%), reassuring on durability.
At 7 years. The newest report extends this picture into longer follow-up.
Why it matters for central Gujarat. As TAVR becomes more available regionally, younger low-risk patients and families increasingly ask about long-term valve durability. These data support TAVR as a durable option in appropriately selected low-risk patients, while reinforcing Heart Team shared decision-making and attention to valve morphology, access anatomy, and life expectancy.